Physician profile
Assif Rozovsky
NPI 1962507251
$2,096.92
in general payments reported to CMS, 2019-2025
20 companies · $330 in 2025
The $330 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $468 · 2020: $261 · 2021: $248 · 2022: $315 · 2023: $223 · 2024: $250 · 2025: $330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $764 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.00 · Grant: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $763.69 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.00 |
| Grant | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $778.49 | 2019-2025 | Skyrizi, Rinvoq, Viberzi |
| Janssen Biotech, INC. | $353.53 | 2019-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $232.25 | 2019-2024 | Xifaxan, Trulance |
| Pfizer INC. | $203.53 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $72.21 | 2020-2023 | Gattex |
| Gilead Sciences, INC. | $69.59 | 2020-2022 | |
| Ironwood Pharmaceuticals, INC | $48.29 | 2019-2020 | |
| Celgene Corporation | $44.78 | 2024 | Zeposia |
| Lilly USA, LLC | $44.66 | 2024-2025 | Omvoh |
| Romark Laboratories, Lc | $42.83 | 2020 | |
| Daiichi Sankyo INC. | $39.73 | 2019-2021 | |
| Shionogi INC | $36.14 | 2019 | |
| Qol Medical, LLC | $32.36 | 2019 | |
| Evoke Pharma, INC. | $22.94 | 2025 | |
| Fresenius Kabi USA, LLC | $17.23 | 2023 | Idacio |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $15.91 | 2022 | |
| Ferring Pharmaceuticals INC. | $13.95 | 2022 | |
| Merck Sharp & Dohme LLC | $12.66 | 2020 | |
| Shire North American Group INC | $11.06 | 2019 | |
| Phathom Pharmaceuticals, INC. | $4.78 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Assif Rozovsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.